GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
China50 participantsStarted 2026-06-25
Plain-language summary
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma.
Participants will undergo GPRC5D-targeted PET/CT, 18F-FDG PET/CT, and 68Ga-BCMA PET/CT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment.
The study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET/CT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults with confirmed or suspected plasma cell disorders, including multiple myeloma.
* Healthy volunteers eligible for PET/CT imaging may also be enrolled.
* Availability of recent clinical laboratory results within 1 week prior to imaging, when applicable.
* Ability to undergo PET/CT imaging procedures.
* Ability to understand the study requirements and provide written informed consent.
Exclusion Criteria:
* History of other active malignant tumors, unless considered clinically insignificant by the investigator.
* Pregnant or breastfeeding women.
* Inability to understand study procedures or comply with imaging examinations.
* Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or image interpretation.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Diagnostic Accuracy of GPRC5D-Targeted PET/CT for Detection of Disease Lesions
Timeframe: Within 5 days after completion of all PET/CT imaging examinations
2
Incidence and Severity of Adverse Events Following GPRC5D-Targeted Radiotracer Administration
Timeframe: From radiotracer administration to 30 days after PET/CT imaging